Scientific Reports (Feb 2017)

ZEB1 regulates glioma stemness through LIF repression

  • Lincoln A. Edwards,
  • Aiguo Li,
  • Dror Berel,
  • Mecca Madany,
  • Nam-Ho Kim,
  • Minzhi Liu,
  • Mitch Hymowitz,
  • Benjamin Uy,
  • Rachel Jung,
  • Minlin Xu,
  • Keith L. Black,
  • Altan Rentsendorj,
  • Xuemo Fan,
  • Wei Zhang,
  • John S. Yu

DOI
https://doi.org/10.1038/s41598-017-00106-x
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 11

Abstract

Read online

Abstract The identification of a stem cell regulatory gene which is aberrantly expressed in glioma and associated with patient survival would increase the understanding of the role of glioma cancer stem cells (GCSCs) in the virulence of gliomas. Interrogating the genomes of over 4000 brain cancers we identified ZEB1 deletion in ~15% (grade II and III) and 50% of glioblastomas. Meta-analysis of ZEB1 copy number status in 2,988 cases of glioma revealed disruptive ZEB1 deletions associated with decreased survival. We identified ZEB1 binding sites within the LIF (stemness factor) promoter region, and demonstrate LIF repression by ZEB1. ZEB1 knockdown in GCSCs caused LIF induction commensurate with GCSC self-renewal and inhibition of differentiation. IFN-γ treatment to GCSCs induced ZEB1 expression, attenuating LIF activities. These findings implicate ZEB1 as a stem cell regulator in glioma which when deleted leads to increased stemness, tumorigenicity and shortened patient survival.